Page 1058 - Hall et al (2015) Principles of Critical Care-McGraw-Hill

References 5

118. Link H, Bohme A, Cornely OA, et al. Antimicrobial ther- 133. Heussel CP, Kauczor HU, Heussel GE, et al. Pneumonia in
apy of unexplained fever in neutropenic patients— guidelines febrile neutropenic patients and in bone marrow and blood
of the Infectious Diseases Working Party (AGIHO) of the stem-cell transplant recipients: use of high-resolution computed
German Society of Hematology and Oncology (DGHO), tomography. J Clin Oncol. 1999;17(3):796-805.
Study Group Interventional Therapy of Unexplained Fever, 134. Caillot D, Casasnovas O, Bernard A, et al. Improved man-
Arbeitsgemeinschaft Supportivmassnahmen in der Onkologie agement of invasive pulmonary aspergillosis in neutropenic
(ASO) of the Deutsche Krebsgesellschaft (DKG-German Cancer patients using early thoracic computed tomographic scan and
Society). Ann Hematol. 2003;82(suppl 2):S105-S117. surgery. J Clin Oncol. January 1997;15(1):139-147.
119. Bow EJ, Mandell LA, Louie TJ, et al. Quinolone-based antibac- 135. Kirkpatrick ID, Greenberg HM. Gastrointestinal complications
terial chemoprophylaxis in neutropenic patients: effect of aug- in the neutropenic patient: characterization and differentiation
mented gram-positive activity on infectious morbidity. National with abdominal CT. Radiology. 2003;226(3):668-674.
Cancer Institute of Canada Clinical Trials Group. Ann Intern 136. Hughes WT, Armstrong D, Bodey GP, et al. 1997 guidelines
Med. 1996;125(3):183-190. for the use of antimicrobial agents in neutropenic patients with
120. Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines unexplained fever. Clin Infect Dis. 1997;25:551-573.
for the use of antimicrobial agents in neutropenic patients with 137. Talcott JA, Siegel RD, Finberg R, Goldman L. Risk assessment
cancer. Clin Infect Dis. 2002;34(6):730-751. in cancer patients with fever and neutropenia: a prospec-
121. American Society of Clinical Oncology. Recommendations tive, two-center validation of a prediction rule. J Clin Oncol.
for the use of hematopoietic colony-stimulating factors: 1992;10(2):316-322.
evidence-based, clinical practice guidelines. J Clin Oncol. 138. Talcott JA, Whalen A, Clark J, Rieker PP, Finberg R. Home
1994;12(11):2471-2508. antibiotic therapy for low-risk cancer patients with fever and
122. Lyman GH, Delgado DJ. Risk and timing of hospitalization neutropenia: a pilot study of 30 patients based on a validated
for febrile neutropenia in patients receiving CHOP, CHOP-R, prediction rule. J Clin Oncol. 1994;12(1):107-114.
or CNOP chemotherapy for intermediate-grade non-Hodgkin 139. Rolston KVI, Rubenstein EB, Freifeld A. Early empirical anti-
lymphoma. Cancer. 2003;98(11):2402-2409. biotic therapy for febrile neutropenic patients at low risk. Infect
123. Blay JY, Chauvin F, Le Cesne A, et al. Early lymphopenia after Dis Clin North Am. 1996;10:223.
cytotoxic chemotherapy as a risk factor for febrile neutropenia. 140. Malik IA, Abbas Z, Karim M. Randomised comparison of oral
J Clin Oncol. 1996;14(2):636-643. ofloxacin alone with combination of parenteral antibiotics in
124. Feld R, Bodey GP. Infections in patients with malignant neutropenic febrile patients. Lancet. 1992;339(8801):1092-1096.
lymphoma treated with combination chemotherapy. Cancer. 141. Malik IA, Khan WA, Karim M, Aziz Z, Khan MA. Feasibility
1977;39(3):1018-1025. of outpatient management of fever in cancer patients with low-
125. Doorduijn JK, van der Holt B, van Imhoff GW, et al. CHOP risk neutropenia: results of a prospective randomized trial. Am
compared with CHOP plus granulocyte colony-stimulating J Med. 1995;98(3):224-231.
factor in elderly patients with aggressive non-Hodgkin’s lym- 142. Minotti V, Gentile G, Bucaneve G, et al. Domiciliary treatment
phoma. J Clin Oncol. 2003;21(16):3041-3050. of febrile episodes in cancer patients: a prospective randomized
126. Markman J, Zanotti K, Webster K, et al. Experience with the trial comparing oral versus parenteral empirical antibiotic treat-
management of neutropenia in gynecologic cancer patients ment. Support Care Cancer. 1999;7(3):134-139.
receiving carboplatin-based chemotherapy. Gynecol Oncol. 143. Petrilli AS, Dantas LS, Campos MC, Tanaka C, Ginani VC,
February 2004;92(2):592-595. Seber A. Oral ciprofloxacin vs. intravenous ceftriaxone admin-
127. Nichols CR, Fox EP, Roth BJ, Williams SD, Loehrer PJ, Einhorn LH. istered in an outpatient setting for fever and neutropenia in
Incidence of neutropenic fever in patients treated with standard- low-risk pediatric oncology patients: randomized prospective
dose combination chemotherapy for small-cell lung cancer trial. Med Pediatr Oncol. 2000;34(2):87-91.
and the cost impact of treatment with granulocyte colony- 144. Mullen CA, Petropoulos D, Roberts WM, et al. Outpatient
stimulating factor. J Clin Oncol. 1994;12(6):1245-1250. treatment of fever and neutropenia for low risk pediatric cancer
128. Cruciani M, Rampazzo R, Malena M, et al. Prophylaxis with flu- patients. Cancer. 1999;86(1):126-134.
oroquinolones for bacterial infections in neutropenic patients: a 145. Rubenstein EB, Rolston K, Benjamin RS, et al. Outpatient treat-
meta-analysis. Clin Infect Dis. 1996;23(4):795-805. ment of febrile episodes in low-risk neutropenic patients with
129. Flowers CR, Seidenfeld J, Bow EJ, et al. Antimicrobial prophy- cancer. Cancer. 1993;71(11):3640-3646.
laxis and outpatient management of fever and neutropenia in 146. Hidalgo M, Hornedo J, Lumbreras C, et al. Outpatient therapy
adults treated for malignancy: American Society of Clinical with oral ofloxacin for patients with low risk neutropenia and
Oncology clinical practice guideline. J Clin Oncol. February 20 fever. Cancer. 1999;85(1):213-219.
2013;31(6):794-810. 147. Klastersky J, Paesmans M, Georgala A, et al. Outpatient oral anti-
130. Sickles EA, Greene WH, Wiernik PH. Clinical presentation biotics for febrile neutropenic cancer patients using a score pre-
of infection in granulocytopenic patients. Arch Intern Med. dictive for complications. J Clin Oncol. 2006;24(25):4129-4134.
1975;135:715-719. 148. Bow EJ. The diagnostic approach to the febrile neutropaenic
131. Walsh TJ. The febrile granulocytopenic patient in the intensive patient: clinical considerations. In: Maschmeyer G, Rolston K,
care unit. Crit Care Clin. 1988;4(2):259-280. eds. Infections in Hematology. Heidelberg: Springer-Verlag;
132. Rubin RH, Greene R. Etiology and managment of the com- 2010:295-318.
promised host with fever and pulmonary infiltrates. Clinical 149. Chang HY, Rodriguez V, Narboni G, Bodey GP, Luna MA,
Approach to Infection in the Compromised Host. New York: Freireich EJ. Causes of death in adults with acute leukemia.
Plenum Press; 1988:131-163. Medicine. 1976;55(3):259-268.

Section05-O-ref.indd 5 1/20/2015 4:51:19 PM